JP2003519096A - Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法 - Google Patents

Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法

Info

Publication number
JP2003519096A
JP2003519096A JP2001516562A JP2001516562A JP2003519096A JP 2003519096 A JP2003519096 A JP 2003519096A JP 2001516562 A JP2001516562 A JP 2001516562A JP 2001516562 A JP2001516562 A JP 2001516562A JP 2003519096 A JP2003519096 A JP 2003519096A
Authority
JP
Japan
Prior art keywords
tumor
binding agent
mammal
muc
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001516562A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003519096A5 (enExample
Inventor
マディヤラカン，ラグパシー
Original Assignee
アルタレックス コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルタレックス コーポレーション filed Critical アルタレックス コーポレーション
Publication of JP2003519096A publication Critical patent/JP2003519096A/ja
Publication of JP2003519096A5 publication Critical patent/JP2003519096A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2001516562A 1999-08-18 2000-08-18 Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法 Withdrawn JP2003519096A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14949299P 1999-08-18 1999-08-18
US60/149,492 1999-08-18
US16471499P 1999-11-11 1999-11-11
US60/164,714 1999-11-11
PCT/US2000/022890 WO2001012217A1 (en) 1999-08-18 2000-08-18 Therapeutic antibody against muc-1 antigen and methods for their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011193430A Division JP2012046518A (ja) 1999-08-18 2011-09-06 Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法

Publications (2)

Publication Number Publication Date
JP2003519096A true JP2003519096A (ja) 2003-06-17
JP2003519096A5 JP2003519096A5 (enExample) 2007-09-27

Family

ID=26846783

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2001516562A Withdrawn JP2003519096A (ja) 1999-08-18 2000-08-18 Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法
JP2011193430A Pending JP2012046518A (ja) 1999-08-18 2011-09-06 Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011193430A Pending JP2012046518A (ja) 1999-08-18 2011-09-06 Ｍｕｃ−１抗原に対する治療用抗体およびその使用方法

Country Status (7)

Country Link
EP (1) EP1204423B1 (enExample)
JP (2) JP2003519096A (enExample)
AT (1) ATE290879T1 (enExample)
AU (1) AU782569B2 (enExample)
DE (1) DE60018761T2 (enExample)
ES (1) ES2239032T3 (enExample)
WO (1) WO2001012217A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005525319A (ja) * 2002-01-24 2005-08-25 バーンズ−ジューイッシュ ホスピタル インテグリン標的イメージング剤
WO2010050528A1 (ja) 2008-10-28 2010-05-06 塩野義製薬株式会社 抗ｍｕｃ１抗体
WO2015068851A1 (ja) * 2013-11-11 2015-05-14 東ソー株式会社 前立腺癌と前立腺肥大症との識別方法
KR20170002500A (ko) 2014-04-28 2017-01-06 이카가쿠 소우야쿠 가부시키가이샤 항muc1 항체 또는 그의 항원 결합성 단편 및 그 용도
JP2020514304A (ja) * 2017-01-27 2020-05-21 グリコトープ ゲーエムベーハー 抗ＭＵＣ１抗体およびＥｒｂＢ阻害剤を用いた抗がん処置

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
WO2002058450A2 (en) 2000-12-22 2002-08-01 Dana-Faber Cancer Institute, Inc. Regulation of cell growth by muc1
US6627664B2 (en) * 2001-01-30 2003-09-30 Altachem Pharma Ltd. Perylenequinones for use as sonosensitizers
US20040110846A1 (en) * 2001-01-30 2004-06-10 Beatrice Leveugle Perylenequinones for use with immunotherapy agents
ES2424131T3 (es) 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
AU2002358246B2 (en) * 2001-10-26 2008-02-28 Oncoquest Pharmaceuticals Inc. Combination therapy for treating disease
DE10256900A1 (de) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
DE10303664A1 (de) * 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
WO2005042573A1 (en) 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
EP1848804B1 (en) * 2005-01-28 2011-10-05 Ramot at Tel Aviv University, Ltd. Anti-muc1 alpha beta antibodies
PT2366400E (pt) 2005-06-28 2016-02-02 Oncothyreon Inc Método de tratamento de doentes com uma vacina à base de glicoproteína mucinosa (muc-1)
US8506931B2 (en) 2005-08-10 2013-08-13 Quest Pharmatech Inc. Perylenequinone derivatives and uses thereof
US8454991B2 (en) 2006-07-24 2013-06-04 Quest Pharmatech Inc. Method and device for photodynamic therapy
WO2008028686A2 (en) 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
WO2008097844A2 (en) 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
WO2008097840A2 (en) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
WO2011135869A1 (ja) 2010-04-28 2011-11-03 塩野義製薬株式会社 新規なｍｕｃ１抗体
JP2014518841A (ja) 2011-02-24 2014-08-07 オンコシレオン インク． アジュバントを備えたｍｕｃ１ベースのグリコリポペプチドワクチン
EP2748302B1 (en) 2011-08-22 2018-08-15 Glycotope GmbH Microorganisms carrying a tumor antigen
EP3794042B1 (en) 2018-05-18 2024-03-27 Daiichi Sankyo Co., Ltd. Anti-muc1- exatecan antibody-drug conjugate

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001773A1 (en) * 1992-07-06 1994-01-20 Biomira Inc. Photoactivation of proteins for conjugation purposes
WO1994011508A2 (en) * 1992-11-13 1994-05-26 Cancer Research Fund Of Contra Costa Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
WO1998033470A2 (en) * 1997-01-10 1998-08-06 Altarex Corp. Substituted perylenequinones for use in photodynamic therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020841A1 (en) * 1992-04-13 1993-10-28 Dana-Farber Cancer Institute, Inc. Antibodies specific for carcinoma-associated antigens
DE19534630A1 (de) * 1995-09-18 1997-03-20 Max Delbrueck Centrum Monoklonale Antikörper gegen epitheliales Muzin (MUC1)
WO1997042973A1 (en) * 1996-05-15 1997-11-20 Altarex, Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
EP1056472A2 (en) * 1998-02-13 2000-12-06 BASTERT, Gunter, Prof.Dr.med.Dr.h.c. Specific antibodies against mammary tumor-associated mucin, method for production and use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994001773A1 (en) * 1992-07-06 1994-01-20 Biomira Inc. Photoactivation of proteins for conjugation purposes
WO1994011508A2 (en) * 1992-11-13 1994-05-26 Cancer Research Fund Of Contra Costa Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
WO1998033470A2 (en) * 1997-01-10 1998-08-06 Altarex Corp. Substituted perylenequinones for use in photodynamic therapy

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005525319A (ja) * 2002-01-24 2005-08-25 バーンズ−ジューイッシュ ホスピタル インテグリン標的イメージング剤
JP2010248248A (ja) * 2002-01-24 2010-11-04 Barnes-Jewish Hospital インテグリン標的イメージング剤
WO2010050528A1 (ja) 2008-10-28 2010-05-06 塩野義製薬株式会社 抗ｍｕｃ１抗体
WO2015068851A1 (ja) * 2013-11-11 2015-05-14 東ソー株式会社 前立腺癌と前立腺肥大症との識別方法
KR20170002500A (ko) 2014-04-28 2017-01-06 이카가쿠 소우야쿠 가부시키가이샤 항muc1 항체 또는 그의 항원 결합성 단편 및 그 용도
US10239950B2 (en) 2014-04-28 2019-03-26 Medicinal Chemistry Pharmaceuticals, Co., Ltd. Anti-MUC1 antibody or antigen-binding fragment thereof and uses thereof
JP2020514304A (ja) * 2017-01-27 2020-05-21 グリコトープ ゲーエムベーハー 抗ＭＵＣ１抗体およびＥｒｂＢ阻害剤を用いた抗がん処置

Also Published As

Publication number Publication date
AU6921100A (en) 2001-03-13
ATE290879T1 (de) 2005-04-15
WO2001012217A1 (en) 2001-02-22
DE60018761T2 (de) 2006-02-02
EP1204423A1 (en) 2002-05-15
AU782569B2 (en) 2005-08-11
JP2012046518A (ja) 2012-03-08
EP1204423B1 (en) 2005-03-16
WO2001012217A9 (en) 2002-06-27
ES2239032T3 (es) 2005-09-16
DE60018761D1 (de) 2005-04-21

Similar Documents

Publication Publication Date Title
US6716966B1 (en) Therapeutic binding agents against MUC-1 antigen and methods for their use
US7147850B2 (en) Therapeutic binding agents against MUC-1 antigen and methods for their use
AU782569B2 (en) Therapeutic binding agents against MUC-1 antigen and methods of their use
US8444974B2 (en) Use of antibodies for the vaccination against cancer
TWI672318B (zh) 葉酸受體１抗體類和免疫共軛物類及彼等之用途
JP2002515235A (ja) 坑アミロイド抗体を用いるアミロイドの除去方法
JP2002518347A (ja) 前立腺癌治療のための免疫療法組成物および方法
WO1992007466A1 (en) Synergistic therapy with combinations of anti-tumor antibodies and biologically active agents
EP1056472A2 (en) Specific antibodies against mammary tumor-associated mucin, method for production and use
JP2000503003A (ja) 多段階カスケード増強ワクチンの効果を高めるための免疫接合体の使用
CZ20021707A3 (cs) Pouľití protilátek pro výrobu farmaceutického přípravku vhodného jako vakcína
O'BOYLE et al. Specificity analysis of murine monoclonal antibodies reactive with Tn, sialylated Tn, T, and monosialylated (2→ 6) T antigens
JP2002518342A (ja) 抗原を変化させることにより免疫応答を産生する治療組成物
JP2526217B2 (ja) 腫瘍会合性糖蛋白に対するモノクロ−ナル抗体およびそれらの製法
JP2007252372A (ja) モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ、医薬組成物ならびに診断試薬
CA2380936A1 (en) Therapeutic antibody against muc-1 antigen and methods for their use
JPH10508831A (ja) ビタミンｂ１２／トランスコバラミンｉｉレセプターおよび結合部位に対する抗レセプターおよび増殖阻止剤
US20040265318A1 (en) Use of antibodies for the vaccination against cancer
JP3006943B2 (ja) 抗糖脂質糖鎖モノクローナル抗体
KR20080113215A (ko) 단일클론 항체 및 이를 코딩하는 유전자, 하이브리도마, 의약 조성물 및 진단 시약

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20031226

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20031226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040220

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20050420

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070810

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100812

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101108

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101209

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110111

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110906

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20111013